Who are Folfox plus Bevacizumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/folfox-plus-bevacizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Folfox plus Bevacizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Folfox plus Bevacizumab (Folfox plus Bevacizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapy and angiogenesis inhibitor. Area: Oncology.

phase 2 chemotherapy and angiogenesis inhibitor VEGF, DNA synthesis and repair pathways Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Folfox plus Bevacizumab (Folfox plus Bevacizumab) — Canadian Cancer Trials Group. FOLFOX plus Bevacizumab inhibits angiogenesis and disrupts tumor blood supply through VEGF inhibition, while FOLFOX induces DNA damage and apoptosis in rapidly dividing cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Folfox plus Bevacizumab TARGET	Folfox plus Bevacizumab	Canadian Cancer Trials Group	phase 2	chemotherapy and angiogenesis inhibitor	VEGF, DNA synthesis and repair pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapy and angiogenesis inhibitor class)

Canadian Cancer Trials Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Folfox plus Bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/folfox-plus-bevacizumab. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing